Moderna Inc said on Tuesday its experimental flu vaccine did not meet the criteria for "early success" in a late-stage trial, and its shares fell 4%. The U.S. biotech company at its vaccine day meeting in Boston also said it expects to have six major vaccines on the market in the next few years. Its COVID-19 shot is currently the company’s lone marketed product.
About the Author
